Xperix엑스페릭스
317770 · KOSDAQ · ₩317770 · 엑스페릭스
What brokers say about Xperix
Calculated by JONBUR from publicly available broker reports. Reports belong to their publishers. Not financial advice. Includes brokers that publish research publicly; some brokers' reports are client-only and not included.
AI summary of public information
An AI summary of the public information on this company: filed financial statements, filings, prices and news headlines. It doesn't use broker reports; their targets and estimates are shown above.
Xperix's revenue has grown strongly since 2023, but it still runs operating losses and is raising capital and issuing convertible bonds.
Xperix, a KOSDAQ-listed maker of biometric devices such as fingerprint enrollment units and passport readers, reported trailing revenue of ₩25.0B through H1 2026 with an operating loss of ₩1.3B and a small net profit of ₩0.3B. The filings show a heavy financing load: borrowings of ₩32.6B against cash of ₩12.2B, and negative free cash flow of ₩3.6B. Shares closed at ₩2,390 on 2026-10-26, down 36.5% over one year and well below the 52-week high of ₩4,735.
What stands out
- Revenue rose 45.7% in 2025 to ₩21.5B, but the company posted a net loss of ₩19.5B that year.
- Trailing operating margin is -5.3%, and the reported net profit depends on items other than core operations.
- Trailing P/E is 253.7 and P/B is 0.9; the data gives no fair value estimate.
- Recent filings include multiple convertible bond issues, conversion price adjustments, a rights offering and a small-scale public offering, pointing to ongoing fundraising.
- Headlines report that a sale of a subsidiary stake has stalled and that a major shareholder has exited, and foreign ownership is 2.4%.
What to watch
- Whether the rights offering and public offering are completed and how they affect the share count and dilution.
- Progress on the stalled subsidiary stake sale and any further conversion price adjustments on the convertible bonds.
- Next periodic results, to see whether operating income turns positive and free cash flow improves against ₩32.6B in borrowings.
Data as of Oct 26, 2026 · written 4d ago
This is not financial advice.
Also known as: Xperix / 엑스페릭스 / 317770 / KRX:317770
Source: KRX statistical information